Biosyent Financial Statements From 2010 to 2025
| BIOYF Stock | USD 9.04 0.19 2.15% |
Check Biosyent financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biosyent's main balance sheet or income statement drivers, such as , as well as many indicators such as . Biosyent financial statements analysis is a perfect complement when working with Biosyent Valuation or Volatility modules.
Biosyent |
Biosyent Company Operating Margin Analysis
Biosyent's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Biosyent Operating Margin | 0.29 % |
Most of Biosyent's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biosyent is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Biosyent has an Operating Margin of 0.2874%. This is 100.82% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The operating margin for all United States stocks is 105.22% lower than that of the firm.
Biosyent Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biosyent's current stock value. Our valuation model uses many indicators to compare Biosyent value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biosyent competition to find correlations between indicators driving Biosyent's intrinsic value. More Info.Biosyent is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.67 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Biosyent is roughly 1.49 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biosyent's earnings, one of the primary drivers of an investment's value.About Biosyent Financial Statements
Biosyent stakeholders use historical fundamental indicators, such as Biosyent's revenue or net income, to determine how well the company is positioned to perform in the future. Although Biosyent investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biosyent's assets and liabilities are reflected in the revenues and expenses on Biosyent's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biosyent. Please read more on our technical analysis and fundamental analysis pages.
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada. Biosyent operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Biosyent Pink Sheet
Biosyent financial ratios help investors to determine whether Biosyent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biosyent with respect to the benefits of owning Biosyent security.